ProCE Banner Activity

STARTER-NET: Phase III Study of Everolimus ± Lanreotide for Unresectable or Recurrent GEP-NET

Conference Coverage
Slideset

In the phase III STARTER-NET trial, everolimus plus lanreotide was associated with significantly prolonged PFS vs everolimus monotherapy and had a manageable toxicity profile in patients with unresectable or recurrent GEP-NETs.

Released: February 04, 2025

Expiration: August 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.

Boehringer Ingelheim Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis Pharmaceuticals Corporation